Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,507.47
(
0.85%
)
US TECH 100
28,836.00
(
0.87%
)
Dow Jones
50,065.33
(
0.75%
)
Brent Oil
102.61
(
-1.04%
)
Bitcoin
81,352.80
(
2.61%
)
News Focus
News Focus
Post# of 257560
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122977
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 142515

Thursday, 06/21/2012 6:01:29 PM

Thursday, June 21, 2012 6:01:29 PM

Post# of 257560
FDA issues CRL for Xarelto in ACS:

http://finance.yahoo.com/news/fda-issues-complete-response-letter-214500851.html

This outcome is not especially surprising insofar as the FDA advisory panel rejected Xarelto for this indication by a 6-4 vote (#msg-75925282).

JNJ has a separate NDA submitted for Xarelto in the PCI sub-indication of ACS, a bifurcation of the ACS indication that looks pretty smart in hindsight (#msg-75916451).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today